Alkem Laboratories Limited

rs,

19th March, 2025 To, The Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. Scrip Code: 539523 National Stock Exchange of India Limited Excha

INR 125

operations Outlook for growth 2 <a> _ ALKEM _ Inspiring Healthier Lives Alkem at a glance INR 125+ Bn Revenue from global operations in FY24 50+ Years of strong growth in Pharma industry (Est. i

INR 555

in Pharma industry (Est. in 1973) 5th Largest Pharma company in India in terms of market share INR 555+ Bn market capitalization as of Feb 2025 Predominantly India focus 10+ Technology platform Exp

70%

ion as of Feb 2025 Predominantly India focus 10+ Technology platform Experienced leadership ~70% revenue contribution from India Investment in growing business verticals like Biosimilars and Med

17%

ata 3 <a> _ ALKEM _ Inspiring Healthier Lives Alkem has demonstrated strong trajectory with ~17% growth CAGR b/w FY09-24; “Next Alkem” created every 5 years Alkem sales, INR Mn1 ~2.4x ~1.7x 1

2.4x

tory with ~17% growth CAGR b/w FY09-24; “Next Alkem” created every 5 years Alkem sales, INR Mn1 ~2.4x ~1.7x 124,392 72,658 ~2.6x 30,330 11,842 FY09 FY14 FY19 FY24 1. Including revenue from E

1.7x

th ~17% growth CAGR b/w FY09-24; “Next Alkem” created every 5 years Alkem sales, INR Mn1 ~2.4x ~1.7x 124,392 72,658 ~2.6x 30,330 11,842 FY09 FY14 FY19 FY24 1. Including revenue from Enzene

2.6x

FY09-24; “Next Alkem” created every 5 years Alkem sales, INR Mn1 ~2.4x ~1.7x 124,392 72,658 ~2.6x 30,330 11,842 FY09 FY14 FY19 FY24 1. Including revenue from Enzene Source: Internal data 4

2x

FY19 FY24 1. Including revenue from Enzene Source: Internal data 4 CAGR FY10-24 ~17% • ~2x growth in topline as well as market cap=> “next Alkem” created every five years Three key pilla

₹ 1 billion

shed at Taloja Taxim became India's first anti-infective drug to surpass annual sales figure of ₹ 1 billion in the domestic market Filed the first ANDA in the US for the drug Amlodipine • --------· ----

₹ 2 billion

1 2012 2014 2009 2010 Successfully completed Initial Public Offering (IPO) Clavam surpassed ₹ 2 billion domestic sales milestone Acquired an API manufacturing facility in the US ·~~ I .,_ . , ~

200 million

---• --------• ------• 2018 2020 2021 2023 2022 2019 Revenue from the US market crossed US$ 200 million in annual sales Crossed the revenue milestone of US$ 1 billion Started a new biologic/ biosimil